HB Human BioScience

Executive Summary

HB Human BioScience is a private preclinical biopharmaceutical company based in São Paulo, Brazil, focused on developing biologics for oncology and autoimmune diseases. Founded in 2010, the company operates with a lean team of 10-50 employees and has no disclosed funding or valuation. Despite limited public information, its positioning in high-growth therapeutic areas suggests potential for partnerships or licensing deals. However, the lack of disclosed pipeline, regulatory milestones, or financial backing warrants cautious optimism. The company's preclinical stage implies significant development risk before any revenue generation or regulatory approval.

Upcoming Catalysts (preview)

• TBDLead asset IND submission or preclinical data release20% success
• Q3 2026Series A or Seed funding round announcement30% success
• Q4 2026Research partnership with larger biopharma25% success